Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Non-small cell lung cancer in countries of Central and Southeastern Europe : diagnostic procedures and treatment reimbursement surveyed by the Central European Cooperative Oncology Group
Authors:ID Ryška, Ales (Author)
ID Buiga, Rares (Author)
ID Fakirova, Albena (Author)
ID Kern, Izidor, Klinika Golnik (Author)
ID Olszewski, Włodzimierz (Author)
ID Plank, Lukas (Author)
ID Seiwerth, Sven (Author)
ID Toth, Erika (Author)
ID Zivka, Eri (Author)
ID Thallinger, Christiane (Author)
ID Zielinski, Christoph (Author)
ID Brčić, Luka (Author)
Files:URL URL - Source URL, visit http://theoncologist.alphamedpress.org/content/23/12/e152
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:This article analyzes the availability of different diagnostic procedures of non-small cell lung cancer (NSCLC) and the reimbursement landscape of drugs for NSCLC in countries of central and southeastern Europe (CEE). A survey was conducted by the Central European Cooperative Oncology Group. Results of the survey show that both availability and reimbursement of diagnoses of molecular alterations in NSCLC, the detection of which is essential for therapeutic decisions, varies widely between countries of CEE. Not only is "reflex" testing often substituted by analyses performed only "on demand," but reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. It was concluded that a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. Implications for Practice. This article provides an overview of the limitations in lung cancer treatment in countries of central and southeastern Europe, as well as the reimbursement status of various lung cancer treatment regimens in these countries, which directly impacts treatment options.
Keywords:Non-small cell lung carcinoma -- diagnosis -- economics -- Europe, molecular diagnostic techniques, precision medicine, Central Europe, Southeastern Europe, reimbursement
Year of publishing:2018
Publication status in journal:Published
Article version:Publisher's version of article
Publisher:AlphaMed Press
Number of pages:str. e152-e158
Numbering:Vol. 23, no. 12
Source:ZDA
PID:20.500.12556/DiRROS-12621 New window
UDC:616-006
ISSN on article:1549-490X
DOI:10.1634/theoncologist.2018-0008 New window
COBISS.SI-ID:2048460913 New window
Copyright:©AlphaMed Press 2018
Note:Soavtor iz Slovenije: Izidor Kern; Nasl. z nasl. zaslona; Opis vira z dne 27. 3. 2019;
Publication date in DiRROS:09.11.2020
Views:984
Downloads:218
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:The oncologist
Shortened title:Oncologist
Publisher:AlphaMed Press
ISSN:1549-490X
COBISS.SI-ID:521539609 New window

Secondary language

Language:Undetermined
Keywords:nedrobnocelični karcinom pljuč -- diagnostika -- ekonomika -- Evropa, molekularne diagnostične tehnike, personalizirana medicina, srednja Evropa, jugovzhodna Evropa, povračilo stroškov


Back